Thursday, Jul 09, 2020 | Last Update : 05:54 PM IST

107th Day Of Lockdown

Maharashtra2237241231929448 Tamil Nadu118594711161636 Delhi102831742173165 Gujarat37636267441978 Uttar Pradesh2996819627313 Telangana2761216287313 Karnataka2681511100417 West Bengal2383715790804 Rajasthan2140416575472 Andhra Pradesh211979745252 Haryana1799913645279 Madhya Pradesh1562711768622 Bihar12525933898 Assam12523833016 Odisha10097670354 Jammu and Kashmir89315399143 Punjab67494554175 Kerala5895345228 Chhatisgarh3415272814 Uttarakhand3230262143 Jharkhand3018210422 Goa190311568 Tripura171612481 Manipur14307710 Himachal Pradesh107876410 Puducherry104351714 Nagaland6443030 Chandigarh4924017 Arunachal Pradesh270922 Mizoram1971390 Sikkim125650 Meghalaya94432
  Metros   Delhi  14 Nov 2017  Cost of treatment of diabetes escalates due to high demand of insulin

Cost of treatment of diabetes escalates due to high demand of insulin

THE ASIAN AGE. | SHASHI BHUSHAN
Published : Nov 14, 2017, 2:24 am IST
Updated : Nov 14, 2017, 2:24 am IST

As per the study, sales of insulin have increased from Rs 218.7 crore to Rs 467.8 crore between 2012 and 2014.

The study aimed at sales trends of all top selling drugs for the past nine years, between 2008 and 2016, with emphasis on anti-diabetic drugs. (Photo: Pixabay)
 The study aimed at sales trends of all top selling drugs for the past nine years, between 2008 and 2016, with emphasis on anti-diabetic drugs. (Photo: Pixabay)

New Delhi: A recent study revealed that there has been a substantial escalation in the overall cost of treating diabetes in the country.

As per the study, sales of insulin have increased from Rs 218.7 crore to Rs 467.8 crore between 2012 and 2014. The study claimed primary reasons for this escalation includes reduced physicians’ tendency to prescribe insulin to diabetics, more diabetics having complications and aggressive marketing by pharmaceutical companies.

A study on the nationwide trends in the sales of anti-diabetic oral drugs and insulin was led by Dr Prof Anoop Misra, chairperson, Fortis C-DOC Hospital for Diabetes and Allied Specialities and president, National Diabetes Obesity and Cholesterol Foundation (N-DOC), The research aimed to study the sales trends of all top selling drugs (20 brands) for the past nine years (between Dec. 2008 and Dec. 2016), with emphasis on anti-diabetic drugs.

It found that from 2008 to 2012, sales of insulin increased from Rs 151.2 crore to Rs 218.7 crores (44 per cent growth).

“In this context, it is important to note that chronic kidney disease due to diabetes is more prevalent among Asian Indians, and increasingly being diagnosed, necessitating insulin therapy in several patients,” as per the study.

 According to the study, between 2014 and 2016, sales of insulin continued to see an upward trend from Rs 467.8 crore to Rs 842 crore (80 per cent increase) due to availability of new basal insulin and newer premix insulin to armamentarium.

“Our study shows that there is an escalation in the overall cost of treating diabetes in India. While there is also a rise in the usage of newer oral drugs and insulin analogues, affordability and accessibility of anti-diabetic therapy to socio-economic stratum remains inadequate.

India has to take several stringent measures to ensure that there is a balancing mechanism in place, education of physicians, tighter regulations on price control and stricter norms for pharmaceutical companies around new drugs and marketing ethics,” Dr Misra said.

Tags: diabetes, insulin